Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Lung Cancer

Trial Name: A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

Protocol ID: S0819


  Patients must have histologically or cytologically proven primary non-small cell lung cancer (adenocarcinoma, large cell carcinoma, squamous or unspecified).  Disease may be either newly diagnosed or recurrent after previous surgery and/or radiation.

  Patients must not have received for any purpose prior chemotherapy.  Patients must not have received any cetuximab, gefitinib, erlotinib or other investigational agents that target the EGFR pathway.  Patients must not have received for any purpose prior bevacizumab or other VEGF-related agents.  Patients must not have received for any purpose prior chimerized or murine monoclonal antibody therapy or have documented presence of human anti-mouse antibodies (HAMA).

  Translational Medicine Studies: Patients must have tumor tissue available for submission that is sufficient for EGFR FISH testing and must agree to submission of these specimens.  Patients must also agree to submission of specimens for other translational medicine studies.

  Prior radiation is permitted; however, patients must have recovered from all associated toxicities at time of study entry.

  Patients must meet required laboratory values.

  Patients must have no known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies [examples include trastuzumab (Herceptin) and epoetin alpha).

  Patients must be willing to provide prior smoking history.

  No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years.

  Pregnant or nursing women are not eligible for this trial because of the increased risk of fetal harm including fetal death from the chemotherapeutic agents.  Women/men of reproductive potential must not participate unless they have agreed to use an effective contraceptive method during protocol treatment and for at least 6 months following completion of bevacizumab treatment.

Enrollment: About 1, 546 people


Taking part in this study may or may not make your health better.  While doctors hope that this treatment will be more useful against cancer compared to the usual treatment, there is no proof of this yet.  We do know that the information from this study will help doctors learn more about these drugs as a treatment for cancer.  This information could help future cancer patients.


These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Aspirus Regional Cancer Center Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353, or Langlade Cancer Center Research Nurse Debra Witman @ 715-623-9587.

Created: Jan 18, 2013

Updated: Oct 16, 2014

« Return to Trials